

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
WO 01/70254 A1

(51) International Patent Classification<sup>7</sup>: A61K 38/17,  
A61P 3/04, 3/10, 5/48, C07K 14/705

(21) International Application Number: PCT/GB01/01211

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0006864.3 21 March 2000 (21.03.2000) GB

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAIRNS, William,  
John [GB/GB]; GlaxoSmithKline, New Frontiers Science  
Park South, Third Avenue, Harlow, Essex CM19 5AW  
(GB). HOLDER, Julie, Caroline [GB/GB]; Glaxo-  
SmithKline, New Frontiers Science Park South, Third  
Avenue, Harlow, Essex CM19 5AW (GB). PATEL, Lisa  
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: CONNELL, Anthony, Christopher; Corporate  
Intellectual Property, SmithKline Beecham, Two New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:  
27 December 2001

(15) Information about Correction:  
see PCT Gazette No. 52/2001 of 27 December 2001, Sec-  
tion II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/70254 A1

(54) Title: USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

(57) Abstract: The use of NOT1 or NOT1 polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

AN

## USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

**Field of the Invention**

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

**Summary of the Invention**

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a activity or levels.

15

**Description of the Invention**

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

20

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

25

Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

30

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

The invention also relates to polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham) and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4, representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

10 NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence, or other fusion peptide portions. For example, a marker sequence which  
20 facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

30 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (*supra*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242).

- 5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

- 15 The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

- 20 Thus in another aspect, the present invention relates to a diagnostic kit which comprises:
- (a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3, or fragments thereof;
  - (b) a nucleotide sequence complementary to that of (a);
  - (c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or
  - (d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2 or SEQ ID NO:4.
- 30

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.



The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

In a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

5 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a  
10 candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect  
15 of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

20 The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated  
25 with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

30 Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

(c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or

(d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

10 (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;

(c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an interactive process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene  
25 therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging  
30 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

“Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an  
5 Fab or other immunoglobulin expression library.

“Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the  
10 coexisting materials of its natural state is “isolated”, as the term is employed herein.

“Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-  
15 and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

20 “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.

“Polynucleotide” also embraces relatively short polynucleotides, often referred to as  
25 oligonucleotides.

“Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

“Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain  
30 amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,

10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for

15 instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis:

20 *Post-translational Modifications and Aging*", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

- 5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, 10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity 15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 25 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)  
Gap Penalty: 12  
Gap Length Penalty: 4

- 30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the  
 5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide  
 10 deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of  
 15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ  
 20 ID NO:1 or SEQ ID NO:3, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the  
 25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group  
 30 consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of



amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

5 
$$n_a \leq x_a - (x_a \cdot y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

10 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a  
15 polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or  
20 part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

25 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

## Examples

### Example 1 - Analysis of NOT1 and NOT1a expression in human tissues

5

Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyAtract method according to manufacturers instructions (Promega, USA). The poly  
10 A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomers and Superscript II reverse transcriptase according to manufacturers  
15 instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al,  
20 ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl<sub>2</sub>, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase,  
25 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles  
30 of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCCAGTTCCTTTG-3',

- 5 TaqMan probe: 5'-CACTTTACCTTTCTAAGACCTCCTCCCAAGCA-3';  
and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATAACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTTCTCCTGCATTGCTGCC-3'.

10

#### Results

- The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.
- 15

Table 1

	NOT1	NOT1a
20 Brain	++	+
Pituitary	+++	++
Heart	+	+/-
Lung	+	+/-
Liver	+	+
25 Foetal Liver	+	+/-
Kidney	+	+
Skeletal Muscle	++	++
Stomach	+	+
Intestine	+	+
30 Spleen	+	+
Lymphocytes	++	++
Macrophage	-	-
Adipose	+++++	+++++
Pancreas	+	+
35 Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

**Example 2 - Analysis of NOT1 expression in 3T3 cells**

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201). Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1 being 100%.

**Table 2**

T1	100
T2	139
T3	57
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells, an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a  
5 function in maintaining the undifferentiated pre-adipocyte state.

**Claims**

1. The use of a compound selected from:
  - (a) a NOT1 or NOT1a polypeptide;
  - 5 (b) a compound which activates a NOT1 or NOT1a polypeptide; or
  - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,for the manufacture of a medicament for treating:
  - (i) obesity;
  - (ii) insulin resistance;
  - 10 (iii) type 2 diabetes;
  - (iv) impaired glucose tolerance;
  - (v) cachexia; or
  - (vi) liposarcoma.
- 15 2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
- 20 4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
- 25 5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
- 30 7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
- 35 8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

## SEQUENCE LISTING

&lt;110&gt; SmithKline Beecham plc

&lt;120&gt; New Use

&lt;130&gt; P32537.

&lt;160&gt; 4

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 3427

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gctcgcgcac ggctccgcgg tcccttttgc ctgtccagcc ggccgcctgt ccctgctccc	60
tccctccgtg agtgtcggg ttcccttcgc ccagctctcc cacccttacc cgaccccggc	120
gcccgggctc ccagagggaa ctgcacttcg gcagagttga atgaatgaag agagacgcgg	180
agaactccta aggaggagat tggacaggct ggactcccca ttgcttttct aaaaatcttg	240
gaaactttgt ctttcattga attacgacac tgtccacctt taatttcctc gaaaacgcct	300
gtaactcggc tgaagccatg ccttgtgttc aggcgcagta tgggtcctcg cctcaaggag	360
ccagccccgc ttctcagagc tacagttacc actcttcggg agaatacagc tccgatttct	420
taactccaga gtttgtcaag tttagcatgg acctcaccaa cactgaaatc actgccacca	480
cttctctccc cagcttcagt acctttatgg acaactacag cacaggctac gacgtcaagc	540
caccttgctt gtaccaaatg cccctgtccg gacagcagtc ctccattaag gtagaagaca	600
ttcagatgca caactaccag caacacagcc acctgcccc ccagtctgag gagatgatgc	660
cgcactccgg gtcggtttac tacaagccct cctcgcctcc gacgcccacc accccgggct	720
tccagggtgca gcacagcccc atgtgggacg acccgggatc tctccacaac ttccaccaga	780
actacgtggc cactacgcac atgatcgagc agaggaaaac gccagtctcc cgcctctccc	840
tcttctcctt taagcaatcg ccccttgga ccccggtgtc tagttgccag atgcgcttcg	900
acggggccct gcacgtcccc atgaaccgg agcccgccgg cagccaccac gtggtggacg	960
ggcagacctt cgctgtgccc aaccccatte gcaagccgc gtccatgggc ttcccgggcc	1020
tgcagatcgg ccacgcgtct cagctgctcg acacgcaggt gccctcaccg ccgtcgcggg	1080
gtccccctc caacgagggg ctgtgcgctg tgtgtgggga caacgcggcc tgccaacact	1140
acggcggtgc cactgtgag ggctgcaaag gcttctttaa gcgcacagtg caaaaaatg	1200

caaaatacgt gtgttttagca aataaaaaact gcccagtgga caagcgtcgc cggaatcgct	1260
gtcagtagctg ccgatttcag aagtgcctgg ctgttgggat ggtcaaagaa gtggttcgca	1320
cagacagttt aaaaggccgg agaggctgtt tgccctcgaa accgaagagc ccacaggagc	1380
cctctcccc ttcgccccg gtgagtcctga tcagtgcctt cgtcagggcc catgtcgact	1440
ccaacccggc tatgaccagc ctggactatt ccagggtcca ggccaaccct gactatcaaa	1500
tgagtggaga tgacaccag catatccagc aattctatga tctctgact ggctccatgg	1560
agatcatccg gggctgggca gagaagatcc ctggcttcgc agacctgccc aaagccgacc	1620
aagacctgct ttttgaatca gctttcttag aactgtttgt ccttcgatta gcatacaggt	1680
ccaaccaggt ggagggtaaa ctcatctttt gcaatggggg ggtcttgac aggttgcaat	1740
gcgttcgtgg ctttggggaa tggattgatt ccattgttga attctcctcc aacttgaga	1800
atatgaacat cgacatttct gccttctcct gcattgctgc cctggctatg gtcacagaga	1860
gacacgggct caaggaaccc aagagagtgg aagaactgca aaacaagatt gtaaattgtc	1920
tcaaagacca cgtgacttct aacaatgggg ggttgaaccg. cccaattat ttgtccaaac	1980
tggtggggaa gctcccagaa cttcgtaccc ttgacacaca ggggctacag cgcattttct	2040
acctgaaatt ggaagacttg gtgccaccgc cagcaataat tgacaacatt ttctggaca	2100
ctttaccttt ctaagacctc ctccaagca cttcaaagga actggaatga taatggaaac	2160
tgtcaagagg gggcaagtca catgggcaga gatagccgtg tgagcagctt cagctcaagc	2220
tgcccccat ttctgtaacc ctctagccc ccttgatccc taaagaaaac aaacaacaa	2280
acaaaaactg ttgctatttc ctaacctgca ggcagaacct gaaagggcat ttggtctccg	2340
gggcatcctg gatttagaac atggactaca cacaatacag tgggtataaac tttttattct	2400
cagtttaaaa atcagtttgt tgttcagaag aaagattgct ataaggata atgggaaatg	2460
tttggccatg cttggttgtt gcagttcaga caaatgtaac acacacacac atacacacac	2520
acacacacac agagacacat ctttaagggga cccacaagta ttgcccttta acaagacttc	2580
aaagttttct gctgtaaaga aagctgtaat atatagtaaa actaaatggt gcgtgggtgg	2640
catgagtga agaaggcaaa ggcttgtaaa tttacccaat gcagtttggc tttttaaat	2700
attttgtgcc tatttatgaa taaatattac aaattctaaa agataagtgt gtttgcaaaa	2760
aaaaagaaaa taaatacata aaaaagggac aagcatgttg attctagggt gaaaatgtta	2820
taggcacttg ctacttcagt aatgtctata ttatataaat agtatttcag acactatgta	2880
gtctgttaga ttttataaag attggtagtt atctgagctt aaacattttc tcaattgtta	2940
aataggtggg cacaagtatt acacatcaga aaatcctgac aaaagggaca catagtgttt	3000
gtaacaccgt ccaacattcc ttgtttgtaa gtgtgtgatg taccgttgat gttgataaaa	3060
agaaagtta tatcttgatt attttgtgt cttaaagctaa acaaaacttg catgcagcag	3120
cttttgactg tttccagagt gcttataata tacataactc cctggaaata actgagcact	3180
ttgaattttt tttatgtcta aaattgtcag ttaatttatt attttgttg agtaagaatt	3240
ttaatattgc catattctgt agtatttttc ttgtatatt tctagtatgg cacatgatat	3300
gagtcactgc ctttttttct atggtgtatg acagttagag atgctgattt tttttctgat	3360
aaattctttc tttgagaaag acaattttta tgtttacaac aataaaccat gtaaatgaaa	3420
aaaaaaa	3427

&lt;210&gt; 2



&lt;211&gt; 598

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
  1             5             10             15
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
      20             25             30
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
      35             40             45
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
      50             55             60
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
      65             70             75             80
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
      85             90             95
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
      100            105            110
Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
      115            120            125
Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
      130            135            140
Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
      145            150            155            160
His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
      165            170            175
Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
      180            185            190
Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
      195            200            205
Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
      210            215            220
Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
      225            230            235            240
Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
      245            250            255
Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
      260            265            270
Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys

```

275	280	285
Arg Thr Val Gln Lys Asn Ala	Lys Tyr Val Cys Leu Ala Asn Lys Asn	
290	295	300
Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe		
305	310	315
Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp		
325	330	335
Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro		
340	345	350
Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu		
355	360	365
Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr		
370	375	380
Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr		
385	390	395
Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile		
405	410	415
Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys		
420	425	430
Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val		
435	440	445
Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe		
450	455	460
Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly		
465	470	475
Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met		
485	490	495
Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile Ala Ala Leu Ala Met Val		
500	505	510
Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln		
515	520	525
Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly		
530	535	540
Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro		
545	550	555
Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu		
565	570	575
Lys Leu Glu Asp Leu Val Pro Pro Pro Ala Ile Ile Asp Lys Leu Phe		
580	585	590
Leu Asp Thr Leu Pro Phe		

595

&lt;210&gt; 3

&lt;211&gt; 1676

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

atgccttg	ttcaggcgca	gtatgggtcc	tcgcctcaag	gagccagccc	cgctttctcag	60
agctacagtt	accactcttc	gggagaatac	agctccgatt	tcttaactcc	agagtttgtc	120
aagtttagca	tggacctcac	caacactgaa	atcactgcc	ccacttctct	ccccagcttc	180
agtaccttta	tggacaacta	cagcacaggc	tacgacgtca	agccaccttg	cttgtaccaa	240
atgcccctgt	ccggacagca	gtcctccatt	aaggtagaag	acattcagat	gcacaactac	300
cagcaacaca	gccacctgcc	ccccagctct	gaggagatga	tgccgcactc	cgggtcgggt	360
tactacaagc	cctcctcgcc	cccgacgccc	accaccccg	gcttccaggt	gcagcacagc	420
cccatgtggg	acgacccggg	atctctccac	aacttccacc	agaactacgt	ggccactacg	480
cacatgatcg	agcagaggaa	aacgccagtc	tcccgcctct	ccctcttctc	ctttaagcaa	540
tcgccccctg	gcaccccggt	gtctagtgtc	cagatgcgct	tcgacgggce	cctgcacgtc	600
cccatgaacc	cggagcccg	cggcagccac	cacgtgggtg	acgggcagac	cttcgctgtg	660
cccaacccca	ttcgcaagcc	cgcgtccatg	ggcttcccg	gcctgcagat	cggccacgcg	720
tctcagctgc	tcgacacgca	ggtgccctca	ccgccgtcgc	ggggctcccc	ctccaacgag	780
gggctgtgcg	ctgtgtgtgg	ggacaacgcg	gcctgccaac	actacggcgt	gcgcacctgt	840
gagggtgca	aaggcttctt	taagcgca	gtgcaaaaa	atgcaaaata	cgtgtgttta	900
gcaataaaaa	actgcccagt	ggacaagcgt	cgcgggaatc	gctgtcagta	ctgccgattt	960
cagaagtgcc	tggctgttgg	gatgggtcaa	gaagtgggtc	gcacagacag	tttaaaaggc	1020
cggagaggtc	gtttgccctc	gaaaccgaag	agcccacagg	agccctctcc	cccttcgccc	1080
ccggtgagtc	tgatcagtgc	cctcgtcagg	gcccatgtcg	actccaacce	ggctatgacc	1140
agcctggact	attccagggt	ccaggcgaa	cctgactatc	aaatgagtgg	agatgacacc	1200
cagcatatcc	agcaattcta	tgatctcctg	actggctcca	tggagatcat	ccggggctgg	1260
gcagagaaga	tccctggctt	cgcagacctg	cccaaagccg	accaagacct	gctttttgaa	1320
tcagctttct	tagaactggt	tgtccttcga	ttagcataca	gaatatgaac	atcgacattt	1380
ctgccttctc	ctgcattgct	gccctggcta	tggtcacaga	gagacacggg	ctcaaggaac	1440
ccaagagagt	ggaagaactg	caaaacaaga	ttgtaaattg	tctcaaagac	cacgtgactt	1500
tcaacaatgg	gggggtgaac	cgccccatt	atttgtccaa	actgttgggg	aagctcccag	1560
aacttcgtac	cctttgcaca	caggggctac	agcgcatttt	ctacctgaaa	ttggaagact	1620
tggtgccacc	gccagcaata	attgacaaac	ttttcctgga	cactttacct	ttctaa	1676

&lt;210&gt; 4

&lt;211&gt; 455

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
  1              5              10              15
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
      20              25              30
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
      35              40              45
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
      50              55              60
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
      65              70              75              80
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
      85              90              95
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
      100             105             110
Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
      115             120             125
Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
      130             135             140
Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
      145             150             155             160
His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
      165             170             175
Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
      180             185             190
Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
      195             200             205
Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
      210             215             220
Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
      225             230             235             240
Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
      245             250             255
Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
      260             265             270
Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys
      275             280             285
Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn

```

290		295		300
Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe				
305		310		315
Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp				
	325		330	335
Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro				
	340		345	350
Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu				
	355		360	365
Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr				
	370		375	380
Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr				
385		390		395
Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile				
	405		410	415
Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys				
	420		425	430
Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val				
	435		440	445
Leu Arg Leu Ala Tyr Arg Ile				
450		455		

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 01/01211

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61P3/04 A61P3/10 A61P5/48 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)	
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NURR1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\* document member of the same patent family

Date of the actual completion of the international search

11 July 2001

Date of mailing of the international search report

27/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Blanco Urgoiti, B

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 01/01211

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, 6R, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424	
A	WO 98 26063 A (MAIRA MARIO ; DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18)	
P, A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



# INTERNATIONAL SEARCH REPORT


Information on patent family members

International Application No  
PCT/GB 01/01211

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9404675	A	03-03-1994	AU 4950393 A	15-03-1994
WO 9826063	A	18-06-1998	CA 2192754 A	12-06-1998
			AU 5470598 A	03-07-1998
WO 0077202	A	21-12-2000	NONE	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
**WO 01/70254 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17**,  
A61P 3/04, 3/10, 5/48, C07K 14/705

(74) Agent: **CONNELL, Anthony, Christopher**; Corporate  
Intellectual Property, SmithKline Beecham, Two New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(21) International Application Number: **PCT/GB01/01211**

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0006864.3 21 March 2000 (21.03.2000) GB

(71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CAIRNS, William**,  
John [GB/GB]; GlaxoSmithKline, New Frontiers Science  
Park South, Third Avenue, Harlow, Essex CM19 5AW  
(GB). **HOLDER, Julie, Caroline** [GB/GB]; Glaxo-  
SmithKline, New Frontiers Science Park South, Third  
Avenue, Harlow, Essex CM19 5AW (GB). **PATEL, Lisa**  
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance  
Notes on Codes and Abbreviations" appearing at the beginning  
of each regular issue of the PCT Gazette.*

(54) Title: **USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS**

(57) Abstract: The use of NOT1 or NOT1 a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

WO 01/70254 A1

## USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

**Field of the Invention**

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

**Summary of the Invention**

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a activity or levels.

15

**Description of the Invention**

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

20

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

25

Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

30

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

The invention also relates to polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham) and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4, representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

10 NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence, or other fusion peptide portions. For example, a marker sequence which  
20 facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

30 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect  
5 cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be  
10 incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is  
15 recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography  
20 and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of  
25 SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood,  
30 urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242).

5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known  
10 and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition,  
15 such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can  
20 be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:  
(a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or  
25 SEQ ID NO:3, or fragments thereof;  
(b) a nucleotide sequence complementary to that of (a);  
(c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or  
(d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2  
30 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.



The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

In a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

(c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or

(d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

10 (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;

(c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an interactive process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene  
25 therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging  
30 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble  
5 form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.  
10 NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be  
15 used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the  
20 like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject. Wide variations in the needed dosage, however, are to be  
25 expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the  
30 subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

“Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an  
5 Fab or other immunoglobulin expression library.

“Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the  
10 coexisting materials of its natural state is “isolated”, as the term is employed herein.

“Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-  
15 and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

20 “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.

“Polynucleotide” also embraces relatively short polynucleotides, often referred to as  
25 oligonucleotides.

“Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

“Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain  
30 amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,

10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for

15 instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, 10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity 15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 25 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)  
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)  
Gap Penalty: 12  
Gap Length Penalty: 4

30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the  
5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical  
to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may  
include up to a certain integer number of nucleotide alterations as compared to the reference  
sequence. Such alterations are selected from the group consisting of at least one nucleotide  
10 deletion, substitution, including transition and transversion, or insertion, and wherein said  
alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or  
anywhere between those terminal positions, interspersed either individually among the  
nucleotides in the reference sequence or in one or more contiguous groups within the reference  
sequence. The number of nucleotide alterations is determined by multiplying the total number of  
15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent  
identity(divided by 100) and subtracting that product from said total number of nucleotides in  
SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ  
20 ID NO:1 or SEQ ID NO:3, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90  
for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to  
the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence  
encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or  
frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the  
25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the  
reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may  
include up to a certain integer number of amino acid alterations as compared to the reference  
sequence such that the % identity is less than 100%. Such alterations are selected from the group  
30 consisting of at least one amino acid deletion, substitution, including conservative and non-  
conservative substitution, or insertion, and wherein said alterations may occur at the amino- or  
carboxy-terminal positions of the reference polypeptide sequence or anywhere between those  
terminal positions, interspersed either individually among the amino acids in the reference  
sequence or in one or more contiguous groups within the reference sequence. The number of



amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

$$5 \quad n_a \leq x_a - (x_a \cdot y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

10 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a  
15 polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or  
20 part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

25 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

## Examples

### Example 1 - Analysis of NOT1 and NOT1a expression in human tissues

5  
Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyAtract method according to manufacturers instructions (Promega, USA). The poly  
10 A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomers and Superscript II reverse transcriptase according to manufacturers instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000  
15 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al,  
20 ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl<sub>2</sub>, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase,  
25 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles  
30 of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCAGTTCCTTTG-3',

5 TaqMan probe: 5'-CACTTTACCTTTCTAAGACCTCCTCCCAAGCA-3';

and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTTCTCCTGCATTGCTGCC-3'.

10

### Results

The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.

15

Table 1

		NOT1	NOT1a
20	Brain	++	+
	Pituitary	+++	++
	Heart	+	+/-
	Lung	+	+/-
	Liver	+	+
25	Foetal Liver	+	+/-
	Kidney	+	+
	Skeletal Muscle	++	++
	Stomach	+	+
	Intestine	+	+
30	Spleen	+	+
	Lymphocytes	++	++
	Macrophage	-	-
	Adipose	+++++	+++++
	Pancreas	+	+
35	Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

#### Example 2 - Analysis of NOT1 expression in 3T3 cells

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were  
 10 grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium  
 15 containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201).  
 20 Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1  
 25 being 100%.

**Table 2**

T1	100
T2	13.9
T3	5.7
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells, an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a  
5 function in maintaining the undifferentiated pre-adipocyte state.

## SEQUENCE INFORMATION

## SEQ ID NO:1

GCTCGCGCACGGCTCCGCGGTCCCTTTTGCTGTCCAGCCGGCCGCTGTCCCTGCTCCCTCCCTCCGTGAGTGTCCGGG  
TTCCCTTCGCCCAGCTCTCCACCCCTACCCGACCCCGGCGCCCGGGCTCCCAGAGGGAACCTGCACCTTCGGCAGAGTTGA  
5 ATGAATGAAGAGAGACGCGGAGAACTCCTAAGGAGGAGATTGGACAGGCTGGACTCCCCATTGCTTTTCTAAAAATCTTG  
GAAACTTTTGCTCTTATTGAATTACGACACTGTCCACCTTTAATTTCTCTCGAAAAAGCCTGTAACTCGGCTGAAGCCATG  
CCTTGTGTTCAGGCGCAGTATGGGTCTCGCTCAAGGAGCCAGCCCCGCTTCTCAGAGCTACAGTTACCACTCTTCGGG  
AGAATACAGCTCCGATTTCTTAACTCCAGAGTTTGTCAAGTTTAGCATGGACCTCACCAACACTGAAATCACTGCCACCA  
CTTCTCTCCCCAGCTTCAGTACCTTTATGGACAACACTACAGCACAGGCTACGACGTCAAGCCACCTTGCTTGTACCAAATG  
10 CCCCTGTCCGGACAGCAGTCTCCATTAAAGGTAGAAGACATTGAGATGCACAACTACCAGCAACACAGCCACCTGCCCCC  
CCAGTCTGAGGAGATGATGCCGCACTCCGGGTGCGTTTACTACAAGCCCTCTCGCCCCGAGCCGCCACCACCCCGGGCT  
TCCAGGTGCAGCACAGCCCCATGTGGGACGACCCGGGATCTCTCCACAACCTTCACCAGAACTACGTGGCCACTACGCAC  
ATGATCGAGCAGAGGAAAACGCCAGTCTCCGCGCTCTCCCTCTTCTCTTAAAGCAATCGCCCCCTGGCACCCCGGTGTC  
TAGTTGCCAGATGCGCTTCGACGGGCCCCCTGCACGTCCCCATGAACCCGGAGCCCGCCGGCAGCCACCACGTGGTGGACG  
15 GGCAGACCTTCGCTGTGCCAACCCCATTCGCAAGCCCGCTCCATGGGCTTCCGGGCTGAGATCGGCCACGCGTCT  
CAGCTGTCTGACACGAGGTGCCCTCACCGCGCTCGCGGGGCTCCCCCTCAACGAGGGGCTGTGCGCTGTGTGTGGGA  
CAACGCGGCTGCCAACACTACGGCGTGGCACCTGTGAGGGCTGCAAAGGCTTCTTTAAGCGCAGGTGCAAAAAATG  
CAAAATACGTGTGTTTAGCAAATAAAAACTGCCAGTGGACAAGCGTCGCCGAATCGCTGTGAGTACTGCCGATTTAG  
AAGTGCTGGCTGTGGGATGGTCAAAGAAGTGGTTCGCACAGACAGTTTAAAAGGCCGAGAGGTGTTTGCCTCGAA  
20 ACCGAAGAGCCACAGGAGCCCTCTCCCCCTTCGCCCCGGTGAGTCTGATCAGTGCCCTCGTCAGGGCCCATGTGCACT  
CCAACCCGGCTATGACCAGCTGGACTATTCCAGGTTCCAGGCGAACCTGACTATCAAATGAGTGGAGATGACACCAG  
CATATCCAGCAATTCTATGATCTCCTGACTGGCTCCATGGAGATCATCCGGGGCTGGGCAGAGAAGATCCCTGGCTTCGC  
AGACCTGCCCCAAGCCGACCAAGACCTGCTTTTGAATCAGCTTTCTTAGAACTGTTTGTCTTCGATTAGCATACAGGT  
CCAACCCAGTGGAGGGTAACTCATCTTTTGCAATGGGGTGGTCTTGACAGGTTGCAATGCGTTGCTGGCTTTGGGGA  
25 TGGATTGATTCCATTGTTGAATTCTCCTCAACTGTCAGAAATATGAACATCGACATTTCTGCCTTCTCCTGCATTGCTGC  
CCTGGCTATGGTACAGAGAGACACGGGCTCAAGGAACCCAGAGAGTGAAGAAGCTGCAAAACAAGATTGTAAATTGTC  
TCAAAGACCACGTGACTTTCAACAATGGGGGGTTGAACCGCCCCAATTATTTGTCCAACTGTTGGGGAAGCTCCAGAA  
CTTCGTACCTTTTGACACAGGGGCTACAGCGCATTTTCTACCTGAAATTGGAAGACTTGGTGCCACCGCCAGCAATAAT  
TGACAACTTTTCTGGACACTTTACCTTTCTAAGACCTCTCCCAAGCACTTCAAAGGAACTGGAATGATAATGGAAC  
30 TGTCAAGAGGGGCAAGTCACATGGGCAGAGATAGCCGTGTGAGCAGTCTCAGCTCAAGCTGCCCCCATTTCTGTAACC  
CTCCTAGCCCCCTTGATCCCTAAAGAAAAACAACAAACAAACAAACAACTGTTGCTATTTCTAACCTGCAGGCAGAACCT  
GAAAGGGCATTTTGGCTCCGGGGCATCTGGATTAGAACATGGACTACACACAATACAGTGGTATAAACTTTTATTCT  
CAGTTTAAAAATCAGTTTGTGTTTGAAGAAAGATTGCTATAAGGTATAATGGGAAATGTTTGGCCATGCTTGGTTGTT  
GCAGTTCAGACAAATGTAAACACACACACATACACACACACACAGAGACACATCTTAAGGGGACCCACAAGTA  
35 TTGCCCTTTAAACAGACTTCAAAGTTTCTGCTGTAAAGAAAGCTGTAAATATATAGTAAACTAAATGTTGCGTGGGTGG  
CATGAGTTGAAGAAGGCAAAGGCTTGTAAATTTACCCAATGCAGTTTGGCTTTTAAATTATTTGTGCTTATTTATGAA  
TAAATATTACAAATTTAAAGATAAGTGTGTTTGCAAAAAAAGAAAATAAATACATAAAAAAGGGACAAGCATGTTG  
ATTCTAGGTTGAAAATGTTATAGGCACTTGCTACTTCAGTAATGTCTATATTATATAAATAGTATTTAGACACTATGTA  
GTCTGTTAGATTTTATAAAGATTGGTAGTTATCTGAGCTTAAACATTTCTCAATTGTAAATAGGTGGGCAAGTATT  
40 ACACATCAGAAAATCTGACAAAAGGACACATAGTGTGTTGTAACCCGTCCAACATTCTTGTGTTGTAAGTGTGTATG  
TACCGTTGATGTTGATAAAAAGAAAGTTTATATCTTGATTTATTTTGTGTTCTAAAGCTAAACAAAACCTTGCATGCAGCAG

CTTTTGA CTGTTTCCAGAGTGCTTATAATATACATAACTCCCTGGAAATAACTGAGCACTTTGAATTTTTTTATGTCTA  
AAATTGTCAGTTAATTTATTATTTGTTTGAGTAAGAATTTAATATTGCCATATTCTGTAGTATTTTCTTTGTATATT  
TCTAGTATGGCACATGATATGAGTCACTGCCTTTTTTTCTATGGTGTATGACAGTTAGAGATGCTGATTTTTTTCTGAT  
AAATTCTTCTTTGAGAAAGACAATTTTAATGTTTACAACAATAAACCATGTAAATGAAAAAAAAA

5

## SEQ ID NO:2

MPCVQAQYGSSPQGASPASQSYSHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSFSTFMD  
NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYYQHSHPQSEEMPHSGSVYYKPPSSPPTP  
TTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFD  
10 GPLHVPMPNPEPAGSHHVVDGQTFAVENPIRKPA SMGFPGLQIGHASQLLDTQVPSPPSRGSPSNE  
GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLA  
VGMVKEVVRTDSLKGRGRRLPSKPKSPQEPSPPSPVSLISALVRAHVDSNPAMTSLDYSRFQAN  
PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLESAFLELFLRLAYRS  
NPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTERHGLKE  
15 PKRVEELQNKIVNCLKDHVTFNNGGLNRPNYLSKLLGKLPELRTLCTQGLQRI FYLKLEDLVPPP  
AIIDKLFLDTLPF

## SEQ ID NO:3

ATGCCTTGTTGTTTCAGGCGCAGTATGGGTCTCGCCTCAAGGAGCCAGCCCCGCTTCTCAGAGCTA  
20 CAGTTACCACTCTTCGGGAGAATACAGCTCCGATTTCTTA ACTCCAGAGTTTGTCAGTTT TAGCA  
TGGACCTCACCAACACTGAAATCACTGCCACCACTTCTCTCCCCAGCTTCAGTACCTTTATGGAC  
AACTACAGCACAGGCTACGACGTCAAGCCACCTTGCTTGTACCAAATGCCCCTGTCCGGACAGCA  
GTCTCTCATTTAAGGTAGAAGACATTCAGATGCACAACTACCAGCAACACAGCCACCTGCCCCCCC  
AGTCTGAGGAGATGATGCCGCACTCCGGGTGCGTTTACTACAAGCCCTCCTCGCCCCCGACGCCC  
25 ACCACCCCGGGCTTCAGGTGCAGCACAGCCCCATGTGGGACGACCCGGGATCTCTCCACAACTT  
CCACCAGAACTACGTGGCCACTACGCACATGATCGAGCAGAGGAAAACGCCAGTCTCCCGCCTCT  
CCCTCTTCTCCTTTAAGCAATCGCCCCCTGGCACCCCGGTGTCTAGTTGCCAGATGCGCTTCGAC  
GGGCCCCCTGCACGTCCCCATGAACCCGGAGCCCGCGGCAGCCACCACGTGGTGGACGGGCAGAC  
CTTCGCTGTGCCCAACCCCATTCGCAAGCCCGCGTTCATGGGCTTCCCGGGCTTCAGATCGGCC  
30 ACGCGTCTCAGCTGCTCGACACGCAGGTGCCCTCACC GCCGTGCGGGGCTCCCCCTCCAACGAG  
GGGCTGTGCGCTGTGTGTGGGGACAACGCGGCCTGCCAACACTAEGGCGTGCGCACCTGTGAGGG  
CTGCAAAGGCTTCTTTAAGCGCACAGTGCAAAAAAATGCAAAATACGTGTGTTTAGCAAATAAAA  
ACTGCCCAGTGGAÇAAGCGTCGCCGAATCGCTGT CAGTACTGCCGATTT CAGAAGTGCCCTGGCT  
GTTGGGATGGTCAAAGAAGTGGTTTCGCACAGACAGTTTAAAAGGCCGGAGAGGTGTTTTGCCCTC  
35 GAAACCGAAGAGCCACAGGAGCCCTCTCCCCCTTCGCCCCCGGTGAGTCTGATCAGTGCCCTCG

TCAGGGCCCATGTGCGACTCCAACCCGGCTATGACCAGCCTGGACTATTCCAGGTTCCAGGCGAAC  
CCTGACTATCAAATGAGTGGAGATGACACCCAGCATATCCAGCAATTCTATGATCTCCTGACTGG  
CTCCATGGAGATCATCCGGGGCTGGGCAGAGAAGATCCCTGGCTTCGCAGACCTGCCCCAAAGCCG  
ACCAAGACCTGCTTTTTGAATCAGCTTTCTTAGAACTGTTTGTCTTCGATTAGCATA CAGAATA  
5 TGAACATCGACATTTCTGCCTTCTCCTGCATTGCTGCCCTGGCTATGGTCACAGAGAGACACGGG  
CTCAAGGAACCCAAGAGAGTGAAGAAGTCAAAAACAAGATTGTAAATTGTCTCAAAGACCACGT  
GACTTTCAACAATGGGGGGTTGAACCGCCCCAATTATTTGTCCAAACTGTTGGGGAAGCTCCCAG  
AACTTCGTACCCTTTGCACACAGGGGCTACAGCGCATTCTTACCTGAAATTGGAAGACTTGGTG  
CCACCGCCAGCAATAATTGACAACTTTTCTTGACACTTTACCTTTCTAA

10

## SEQ ID NO:4

MPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTS LPSFSTFMD  
NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYKPS SPPTP  
TTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTFVSSCQMRFD  
15 GPLHVPMPNPEPAGSHHVVDGQTFAVPNPIRKPA SMGFPGLQIGHASQLLDTQVPSPPSRGSPSNE  
GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLA  
VGMVKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPVSLISALVRAHVDSNPAMTSLDYSRFQAN  
PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLR LAYRI.



**Claims**

1. The use of a compound selected from:
  - (a) a NOT1 or NOT1a polypeptide;
  - 5 (b) a compound which activates a NOT1 or NOT1a polypeptide; or
  - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,for the manufacture of a medicament for treating:
  - (i) obesity;
  - (ii) insulin resistance;
  - 10 (iii) type 2 diabetes;
  - (iv) impaired glucose tolerance;
  - (v) cachexia; or
  - (vi) liposarcoma.
- 15 2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
- 20 4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
- 25 5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
- 30 7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide  
35 having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01211

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61P3/04 A61P3/10 A61P5/48 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)	
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NURR1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

11 July 2001,

Date of mailing of the international search report

27/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Blanco Urgoiti, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01211

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424	
A	WO 98 26063 A (MAIRA MARIO ;DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18)	
P,A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application	

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 01/01211

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404675 A	03-03-1994	AU 4950393 A	15-03-1994
WO 9826063 A	18-06-1998	CA 2192754 A AU 5470598 A	12-06-1998 03-07-1998
WO 0077202 A	21-12-2000	NONE	